Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products
ABSTRACT - Purpose. The aim of this study was to identify common trends in the deficiencies identified in the quality part of the dossier during the evaluation of marketing authorisation applications for medicinal products for human use submitted through the EU's centralised procedure. Methods....
Saved in:
Main Authors: | John Joseph Borg (Author), Jean-Louis Robert (Author), George Wade (Author), George Aislaitner (Author), Michal Pirozynski (Author), Eric Abadie (Author), Tomas Salmonson (Author), Patricia Vella Bonanno (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2009-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Authorisation for Fusafungine-Containing Medicines is Revoked
by: Z. A. Alacheva
Published: (2016) -
Risk Management Plan: Expert Review of Applications for Marketing Authorisation in the EAEU Depending on the Type of Medicinal Product (Review)
by: T. M. Bukatina, et al.
Published: (2024) -
Authorised Guide to the Tower of London
by: Loftie, W. J. (William John), 1839-1911 -
Orphan drugs assessment in the centralised procedure
by: Giuseppe Nisticò
Published: (2011) -
Nitrosamines in medicinal products
by: Katarzyna Dominiak, et al.
Published: (2022)